Linatab M Tablet 2.5 mg + 500 mg is a combination oral antidiabetic medication formulated to help manage type 2 diabetes mellitus. It contains Linagliptin 2.5 mg, a DPP-4 inhibitor, and Metformin Hydrochloride 500 mg, a biguanide, providing complementary mechanisms for improved glycemic control. This combination is intended for adult patients whose blood glucose is not adequately controlled with diet, exercise, or monotherapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Dipeptidyl Peptidase-4 (DPP-4) Inhibitor

• Biguanide Antidiabetic

Pharmacology

Linagliptin inhibits the enzyme DPP-4, which breaks down incretin hormones (GLP-1 and GIP). By preventing this degradation, Linagliptin enhances glucose-dependent insulin secretion and suppresses glucagon release, improving both fasting and postprandial blood glucose levels.

Metformin Hydrochloride primarily works by:

• Reducing hepatic glucose production

• Increasing peripheral glucose uptake and utilization

• Decreasing intestinal glucose absorption

Together, the combination targets multiple pathways in glucose regulation, offering a synergistic effect for improved glycemic control with a low risk of hypoglycemia when not combined with insulin or insulin secretagogues.

Indications

Linatab M Tablet is indicated for:

• Adults with type 2 diabetes mellitus requiring dual therapy

• Patients inadequately controlled on diet, exercise, or monotherapy with Metformin or Linagliptin

• Those who may benefit from improved fasting and postprandial glucose control

• As an adjunct to lifestyle modification to reduce the risk of diabetes-related complications

Dosage and Administration

• Adults: Typically, one tablet twice daily with meals to minimize gastrointestinal side effects from Metformin

• Dose adjustments may be necessary for patients with renal impairment, hepatic dysfunction, or other comorbid conditions

• The tablet should be swallowed whole with water and taken at the same time each day for consistent glucose control

• Dosage modification may also be required if used with other antidiabetic medications

Contraindications

• Known hypersensitivity to Linagliptin, Metformin, or any component of the formulation

• Patients with severe renal impairment, metabolic acidosis, or acute conditions that may cause tissue hypoxia (e.g., shock, sepsis)

• Contraindicated in patients with a history of lactic acidosis

Side Effects

Linatab M Tablet is generally well tolerated. Common adverse effects include:

• Gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort (mainly due to Metformin)

• Headache, dizziness, or mild upper respiratory tract infections (associated with Linagliptin)

• Rare but serious effects: lactic acidosis, pancreatitis, or hypersensitivity reactions

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Monitor renal function before initiation and periodically during treatment

• Ensure adequate hydration to reduce the risk of Metformin-related lactic acidosis

• Educate patients about symptoms of pancreatitis or lactic acidosis

• Dose adjustments may be required when used with other antidiabetic drugs

Pregnancy and Lactation

• Use only if clearly needed; safety data during pregnancy are limited

• Breastfeeding is not recommended during treatment due to limited information on excretion in human milk

Storage Conditions

• Store in a cool, dry place below 30°C, protected from light and moisture

• Keep out of reach of children

Mode of Action

Linatab M Tablet 2.5 mg + 500 mg provides dual glycemic control:

• Linagliptin enhances insulin secretion and reduces glucagon levels

• Metformin lowers hepatic glucose production and improves peripheral glucose uptake

This complementary action targets fasting and postprandial hyperglycemia, helping patients maintain stable blood glucose levels and reduce the risk of long-term diabetes complications.